Today’s episode is the first in my new Medication Minute series of this podcast. These shorter episodes will feature information regarding a specific subset of psychiatric medication management; anything from a new drug that is available to important side effects of a medication. On today’s episode, I want to discuss a new medication called valbenazine (Ingrezza), which recently became the first FDA-approved drug to treat tardive dyskinesia.
- Meyer, Jonathan M., MD. “Valbenazine for Tardive Dyskinesia.” Current Psychiatry 16.5 (May 2017): 40-45. Print.
- Hauser, Robert A., MD, MBA, and Et Al. “KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.” American Journal of Psychiatry. N.p., 21 Mar. 2017. Web. 14 July 2017.
- Gelenberg, Alan J., MD. “Valbenazine (Ingrezza): The First Drug Approved to Treat TD.” Biological Therapies in Psychiatry 40.7 (July 2017). Web. 14 July 2017.
- Jankovic, J., and J. Beach. “Long-term Effects of Tetrabenazine in Hyperkinetic Movement Disorders.” Neurology 48.2 (1997): 358-62. Web. 14 July 2017.
- Anonymous. “Valbenazine (Ingrezza) for Tardive Dyskinesia.” The Medical Letter® on Drugs and Therapeutics 59.1521 (May 2017). Web. 14 July 2017.